Hoechst Aktiengesellschaft

John J Grome

Ulrich Gebert

Karl Rudolphi

Elisabeth Defossa

Uwe Heinelt

Harald Furrer

Hiristo Anagnostopulos

Erhard Wolf

Hans-Peter Schubert

Wilfried Schwab

Dirk Seiffge

Werner Thorwart

Ismahan Okyayuz-Baklouti

Erhard Rossmanith

Ernst J Schneider

Barbara Kittner

Ernst-Jurgen Schneider

Elena Porsche-Wiebking

Ralf Kolvenbach

Viera Danielisova

Theophylline derivatives having at least one ether function in the structurally modified methyl radical in the 1-position that are useful in the treatment and prophylaxis of states of shock, new xanthine compounds having this substitution pattern, and processes for their preparation.

Use of theophylline derivatives for the treatment and prophylaxis of states of shock, novel xanthine compounds and processes for their preparation

Compounds of the formula I, ##STR1## in which one of the radicals R.sup.1 and R.sup.3 is an alkynol residue of the formula Ia or Ib ##STR2## are suitable for producing pharmaceuticals having a neuroprotective effect.

Xanthine compounds having terminally animated alkynol side chains

Use of xanthine derivatives for the treatment of nerve damage following an interruption in blood circulation. The invention relates to the use of xanthine derivatives of the formula I ##STR1## in which R.sup.2 is a (C.sub.1 -C.sub.4)-alkyl group and at least one of the symbols R.sup.1 and R.sup.3 is a radical of the formula II or III ##STR2## in which A is CHOH, CO or dioxolane, R.sup.4 is a hydrogen atom or a (C.sub.1 -C.sub.4)-alkyl group and n is 0 to 5, and in which R.sup.5 and R.sup.6 are hydrogen atoms or (C.sub.1 -C.sub.4)-alkyl groups or, together with the nitrogen atom to which they are bonded, form a 5- to 7-membered ring, it being possible for one carbon atom to be replaced by an oxygen or nitrogen atom, m is 1 or 2 and the other radical R.sup.1 or R.sup.3, if appropriate, is a hydrogen atom, a (C.sub.1 -C.sub.6)-alkyl group or a (C.sub.3 -C.sub.6)-alkenyl group, for the preparation of medicaments for the prophylaxis and treatment of nerve damage following an interruption in blood circulation, and novel xanthine derivatives, and to processes for their preparation.

Use of xanthine derivatives for the treatment of nerve damage following

Pyridopyrimidinediones, processes for their preparation and their use as drugs A compound of the formula I: ##STR1## and/or physiologically acceptable salts of the compound of the formula I, and/or optionally stereoisomeric forms of the compound of the formula I, are suitable for the preparation of drugs for the treatment of circulatory disorders and/or neurodegenerative diseases.

Pyridopyrimidinediones, processes for their preparation and their use as

The use of 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine or of physiologically tolerated salts of this compound for the preparation of pharmaceuticals for the prophylaxis and treatment of nerve damage after interruption of the blood circulation is disclosed.

Use of 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine in vascular surgery

The use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas (CCT) The use of xanthine derivatives of the formula I ##STR1## and of their physiologically tolerable salts, in which R.sup.1 is oxoalkyl, hydroxyalkyl or alkyl, R.sup.2 is hydrogen or alkyl and R.sup.3 is hydrogen, alkyl, oxoalkyl or an alkyl having up to 6 carbon atoms, whose carbon chain is interrupted by an oxygen atom, for the production of pharmaceuticals for the treatment of disorders which can occur after cranio-cerebral traumas is described.

Xanthine derivatives for the treatment of secondary nerve cell damage

Novel 3,5-disubstituted 2-isoxazolines and isoxazoles and novel pharmaceuticals are described which are suitable, in particular, for the prophylaxis and/or treatment of pathological, neurodegenerative disorders in humans and animals. Processes for the preparation of these 3,5-disubstituted 2-isoxazolines and isoxazolines and isoxazoles are additionally indicated.

3,5-disubstituted 2-isoxazolines and isoxazoles, agents containing them

Growing community of inventors

Wiesbaden, Germany

John J Grome